LigaChem Biosciences Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
174
- Stock Symbol
-
141080
- Investments
-
7
- Share Price
-
$47.28
- (As of Thursday Closing)
LigaChem Biosciences General Information
Description
LigaChem Biosciences Inc develops new drugs through research. The Company provides business research services, manufacturing and sale of compounds, and drug evaluation.
Contact Information
Website
www.ligachembio.comCorporate Office
- 10, Gukjegwahak 10-ro
- Yuseong-gu
- Daejeon
- South Korea
Corporate Office
- 10, Gukjegwahak 10-ro
- Yuseong-gu
- Daejeon
- South Korea
LigaChem Biosciences Timeline
LigaChem Biosciences Stock Performance
As of 12-Nov-2026, LigaChem Biosciences’s stock price is $47.28. Its current market cap is $1.87B with 39.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $47.28 | $48.93 | $39.61 - $154.80 | $1.87B | 39.6M | 219K | -$3.37 |
LigaChem Biosciences Financials Summary
As of 30-Jun-2026, LigaChem Biosciences has a trailing 12-month revenue of $68.1M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,328,180 | 4,024,884 | 2,341,568 | 1,254,405 |
| Revenue | 68,066 | 99,466 | 92,271 | 26,116 |
| EBITDA | (131,646) | (73,626) | (3,912) | (58,400) |
| Net Income | (123,156) | (52,193) | 5,717 | (56,372) |
| Total Assets | 385,043 | 487,368 | 501,288 | 147,051 |
| Total Debt | 1,677 | 1,909 | 557 | 9,812 |
LigaChem Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
LigaChem Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
LigaChem Biosciences Patents
LigaChem Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234446-A1 | Anti-ceacam5 antibody drug conjugates and uses thereof | Pending | 08-May-2025 | ||
| WO-2026234451-A1 | Anti-lewis y antibody drug conjugates and uses thereof | Pending | 08-May-2025 | ||
| WO-2026234447-A1 | Branched linkers for conjugates | Pending | 08-May-2025 | ||
| WO-2026234453-A1 | Improved linkers for conjugates | Pending | 08-May-2025 | ||
| WO-2026160926-A1 | Pharmaceutical composition comprising oxazolidinone derivative | Pending | 24-Jan-2025 |
LigaChem Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
LigaChem Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
LigaChem Biosciences Investments & Acquisitions (7)
LigaChem Biosciences’s most recent deal was a Later Stage VC with 1STBIO for . The deal was made on 26-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 1STBIO | 26-Jan-2026 | Later Stage VC | Drug Discovery | ||
| Iksuda Therapeutics | 30-Jun-2025 | Later Stage VC | Drug Discovery | ||
| Parataxis Korea | 05-Sep-2023 | PIPE | Other Financial Services | ||
| Parataxis Korea | 03-Mar-2021 | PIPE | Other Financial Services | ||
| S-Alpha Therapeutics | 01-Feb-2020 | Corporate | Drug Discovery |
LigaChem Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.16 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
LigaChem Biosciences Exits (3)
LigaChem Biosciences’s most recent exit was on 05-Sep-2023 from Parataxis Korea. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Parataxis Korea | 05-Sep-2023 | Completed |
|
||
| Parataxis Korea | 03-Mar-2021 | Completed |
|
||
| Geom Therapeutics | 07-Jul-2016 | Merger/Acquisition | Completed |
LigaChem Biosciences FAQs
-
When was LigaChem Biosciences founded?
LigaChem Biosciences was founded in 2006.
-
Where is LigaChem Biosciences headquartered?
LigaChem Biosciences is headquartered in Daejeon, South Korea.
-
What is the size of LigaChem Biosciences?
LigaChem Biosciences has 174 total employees.
-
What industry is LigaChem Biosciences in?
LigaChem Biosciences’s primary industry is Drug Discovery.
-
Is LigaChem Biosciences a private or public company?
LigaChem Biosciences is a Public company.
-
What is LigaChem Biosciences’s stock symbol?
The ticker symbol for LigaChem Biosciences is 141080.
-
What is the current stock price of LigaChem Biosciences?
As of 12-Nov-2026 the stock price of LigaChem Biosciences is $47.28.
-
What is the current market cap of LigaChem Biosciences?
The current market capitalization of LigaChem Biosciences is $1.87B.
-
What is LigaChem Biosciences’s current revenue?
The trailing twelve month revenue for LigaChem Biosciences is $68.1M.
-
What is LigaChem Biosciences’s annual earnings per share (EPS)?
LigaChem Biosciences’s EPS for 12 months was -$3.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
